Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients with Myelofibrosis with Progression or Suboptimal Response: Phase II Safety and Efficacy

Claire N. Harrison, Jacqueline S. Garcia, Tim C.P. Somervaille, James M. Foran, Srdan Verstovsek, Catriona Jamieson, Ruben Mesa, Ellen K. Ritchie, Srinivas K. Tantravahi, Pankit Vachhani, Casey L. O'Connell, Rami S. Komrokji, Jason Harb, Jessica E. Hutti, Leanne Holes, Abdullah A. Masud, Silpa Nuthalapati, Jalaja Potluri, Naveen Pemmaraju

Research output: Contribution to journal › Article › peer-review

55 Scopus citations

Fingerprint

Dive into the research topics of 'Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients with Myelofibrosis with Progression or Suboptimal Response: Phase II Safety and Efficacy'. Together they form a unique fingerprint.

Medicine & Life Sciences